Metastatic Prostate Cancer
Fewer PSA screenings linked to increases in advanced prostate cancer diagnoses
U.S. states with larger declines in PSA screening from 2002 to 2016 also had larger increases in incidence of metastatic prostate cancer at diagnosis, according to a presentation at Genitourinary Cancers Symposium.
FDA lifts clinical hold on trial of CAR-T for metastatic pancreatic, prostate cancers
The FDA lifted its clinical hold on a study evaluating BPX-601 and rimiducid for patients with previously treated metastatic pancreatic or prostate cancers, according to a press release from the agent’s manufacturer.
Rucaparib active in BRCA-mutated metastatic castration-resistant prostate cancer
Rucaparib demonstrated antitumor activity among men with metastatic castration-resistant prostate cancer and a deleterious BRCA alteration, according to results of the phase 2 TRITON2 study published in Journal of Clinical Oncology.
Eight important updates for National Prostate Cancer Awareness Month
National Prostate Cancer Awareness Month is observed every September.
New framework takes genetic testing guidelines for prostate cancer ‘a step further’
All men with metastatic prostate cancer should undergo genetic testing to better inform decisions on precision medicine or clinical trial eligibility, according to recommendations developed at a multidisciplinary consensus conference.
AACR Academy names president-elect
Fellows of the American Association for Cancer Research Academy named Charles L. Sawyers, MD, president-elect for 2020-2021.
FDA approves Rubraca for prostate cancer subset
Addition of atezolizumab to enzalutamide fails to extend OS in metastatic castration-resistant prostate cancer
Atezolizumab in combination with enzalutamide did not extend OS compared with enzalutamide monotherapy among men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 IMbassador250 study presented at the virtual American Association for Cancer Research Annual Meeting.
HSD3B1 genotype linked to worse outcomes in low-volume metastatic prostate cancer
The adrenal-permissive HSD3B1 genotype appeared associated with earlier castration resistance and shorter OS among men with low-volume metastatic prostate cancer, according to results of a retrospective analysis of a randomized phase 3 study published in JAMA Oncology.
Statins alone, with metformin linked to reduced mortality among men with high-risk prostate cancer
Use of statins as monotherapy or in combination with metformin appeared associated with lower mortality among men with high-risk prostate cancer, according to results of a retrospective study published in Cancer Medicine.